diarrhea
second
greatest
caus
mortal
children
worldwid
virus
within
genera
noroviru
sapoviru
famili
calicivirida
signific
caus
gastroenter
human
anim
norovirus
alon
caus
death
per
annum
children
year
age
despit
socioeconom
impact
fastidi
natur
virus
within
genera
significantli
hinder
understand
life
cycl
develop
vaccin
therapeut
porcin
sapoviru
psav
cultiv
member
genu
sapoviru
replic
presenc
porcin
intestin
content
bile
acid
therefor
psav
serv
robust
model
studi
sapoviru
life
cycl
develop
therapeut
intervent
coexist
virus
host
impos
evolutionari
pressur
viru
host
immun
system
therefor
virus
evolv
divers
strategi
creat
suitabl
environ
conduc
exist
either
activ
suppress
cellular
pathway
facilit
replic
prostaglandin
pathway
one
sever
host
pathway
particip
modul
host
respons
infect
replic
life
cycl
virus
exampl
activ
pathway
result
increas
replic
cytomegaloviru
inhibit
replic
parainfluenza
viru
adenoviru
cox
convert
arachidon
acid
releas
phospholipas
cmediat
hydrolysi
plasma
membran
phospholipid
follow
exposur
divers
physiolog
patholog
stimuli
prostaglandin
pg
prostacyclin
thromboxan
three
form
cox
identifi
date
wide
studi
constitut
express
known
synthes
variou
pg
includ
particip
divers
rang
normal
physiolog
process
cytoprotect
gastric
mucosa
regul
renal
blood
flow
bone
metabol
nerv
growth
develop
wound
heal
platelet
aggreg
contrast
rapidli
induc
variou
stimuli
includ
viral
infect
catalyz
synthesi
variou
pg
includ
vari
activ
includ
proangiogen
antiapoptot
properti
biolog
effect
immun
inflamm
exert
bind
gproteincoupl
receptor
plasma
membran
call
e
prostanoid
receptor
recogn
major
prostanoid
produc
immun
nonimmun
cell
act
potent
regul
cellcel
interact
antigen
present
cytokin
product
differenti
surviv
apoptosi
cell
migrat
studi
examin
potenti
role
pathway
regul
sapoviru
life
cycl
demonstr
pathway
induc
psav
replic
induct
occur
follow
express
viral
vpg
proteasepolymeras
propol
protein
demonstr
product
provid
protect
effect
antivir
effector
mechan
nitric
oxid
uncov
new
mechan
enteropathogen
virus
manipul
host
cell
provid
environ
suitabl
effici
viral
growth
determin
whether
pathway
activ
psav
replic
examin
impact
psav
replic
cox
gene
express
mrna
protein
level
markedli
elev
h
postinfect
hpi
concomit
increas
psav
viral
rna
protein
level
wherea
level
transient
increas
hpi
fig
c
level
infect
cell
cultur
supernat
also
significantli
elev
hpi
fig
confirm
whether
observ
increas
solubl
direct
result
psavmedi
induct
effect
select
nonselect
cox
inhibitor
product
examin
fig
importantli
studi
perform
dose
inhibitor
shown
affect
cell
viabil
experiment
condit
use
data
shown
nonselect
inhibitor
indomethacin
select
inhibitor
inhibit
psavmedi
product
dosedepend
manner
ad
either
immedi
remov
viru
inoculum
posttreat
entir
cours
infect
preposttreat
fig
b
contrast
due
revers
natur
inhibitor
pretreat
cell
subsequ
remov
inhibitor
prior
addit
psav
effect
level
product
fig
b
similar
result
also
obtain
rang
cox
inhibitor
fig
data
shown
confirm
direct
role
product
psav
infect
effect
small
interf
rna
sirna
also
examin
transfect
sirna
llcpk
cell
reduc
express
level
respect
target
protein
although
inhibit
intracellular
protein
sirna
transfect
complet
level
releas
sirnatransfect
cell
significantli
reduc
fig
f
result
confirm
induct
cox
enzym
respons
observ
increas
psavinfect
cell
addit
level
sirnamedi
reduct
suffici
significantli
reduc
product
determin
impact
cox
induct
psav
replic
examin
effect
cox
inhibitor
sirna
psav
replic
cell
either
treat
inhibitor
select
nonselect
transfect
sirna
specif
effect
viru
replic
monitor
hpi
examin
viral
titer
well
viral
rna
protein
level
signific
effect
cox
inhibitor
psav
replic
cell
pretreat
inhibitor
remov
prior
infect
pretreat
fig
h
howev
inclus
cox
inhibitor
follow
remov
viru
inoculum
posttreat
entir
cours
infect
preposttreat
result
signific
reduct
psav
replic
fig
h
inhibitor
reduc
level
psav
rna
infecti
viru
hpi
fig
h
contrast
inhibitor
celecoxib
nonselect
inhibitor
indomethacin
show
signific
effect
typic
lead
decreas
viru
yield
rna
synthesi
fig
f
inhibitor
nimesulid
also
test
howev
less
robust
inhibit
psav
replic
observ
data
shown
effect
coxspecif
sirna
psav
replic
also
examin
fig
l
f
transfect
sirna
substanti
effect
psav
replic
sirna
caus
reduct
viral
titer
concomit
decreas
viral
rna
level
viral
protein
product
fig
f
infect
assay
also
demonstr
either
treatment
cell
transfect
sirna
result
signific
decreas
number
psav
antigenposit
cell
fig
combin
data
suggest
enhanc
psav
replic
possibl
via
increas
product
provir
effect
cox
gene
induct
psav
replic
due
sole
product
increas
addit
would
expect
revers
inhibitori
effect
cox
inhibitor
viru
replic
examin
possibl
abil
exogen
restor
psav
replic
treatment
nonselect
inhibitor
indomethacin
inhibitor
examin
addit
exogen
led
dosedepend
restor
psav
infect
viral
rna
level
cell
treat
either
inhibitor
fig
result
confirm
final
product
cox
enzym
mediat
provir
effect
cox
gene
induct
psav
replic
psav
replic
cell
cultur
reli
presenc
bile
acid
includ
glycochenodeoxychol
acid
gcdca
cell
cultur
medium
function
previous
link
effect
bile
acid
innat
immun
respons
infect
howev
recent
studi
indic
initi
conclus
incorrect
psav
remain
sensit
type
interferon
ifn
respons
presenc
bile
acid
bile
acid
function
promot
viru
uncoat
determin
whether
bile
acid
effect
induct
pathway
psav
replic
induct
examin
presenc
absenc
gcdca
follow
transfect
vitrotranscrib
cap
psav
genom
fig
transfect
rna
use
bypass
role
gcdca
viral
entri
uncoat
observ
induc
cell
transfect
vitrotranscrib
cap
psav
genom
rna
irrespect
whether
gcdca
present
absent
fig
expect
inhibitor
reduc
express
replic
psav
fig
data
indic
induct
direct
result
psav
replic
due
supplementari
effect
gcdca
given
observ
psav
replic
requir
induct
pathway
investig
whether
express
viral
protein
alon
suffici
llcpk
cell
transfect
plasmid
carri
psav
gene
includ
gene
express
viral
protein
confirm
via
detect
hemagglutinin
ha
tag
fuse
n
terminu
protein
fig
western
blot
quantitativepcr
qpcr
analysi
level
demonstr
vpg
propol
express
significantli
enhanc
express
led
increas
product
fig
previou
studi
indic
least
one
effect
prostaglandin
product
regul
product
key
molecul
involv
host
defens
mechan
variou
pathogen
includ
protozoan
parasit
fungi
bacteria
virus
also
regulatori
role
mani
stage
develop
inflamm
determin
produc
psav
replic
impact
product
first
examin
level
produc
psav
replic
psavinfect
cell
maintain
low
level
prior
hpi
signific
increas
product
observ
fig
data
suggest
cox
induct
associ
increas
product
may
play
import
role
inhibit
product
psav
replic
examin
possibl
effect
inhibitor
product
psav
infect
also
examin
fig
inhibit
activ
found
lead
concomit
increas
product
psav
replic
could
revers
dosedepend
manner
addit
nitric
oxid
synthas
no
inhibitor
lname
fig
revers
effect
inhibit
lname
also
result
subsequ
restor
psav
infect
level
well
psav
rna
protein
level
fig
e
collect
data
suggest
provir
effect
produc
enzym
result
psav
infect
mediat
inhibit
antivir
effect
viral
infect
numer
host
inflammatori
respons
induc
lead
product
cellular
effector
solubl
factor
ifn
oblig
intracellular
parasit
virus
must
therefor
subvert
andor
avoid
host
respons
infect
order
complet
life
cycl
result
pathogen
includ
virus
evolv
wide
varieti
mechan
enabl
control
cellular
pathway
evad
host
immun
respons
hijack
signal
pathway
facilit
viral
replic
pathogenesi
investig
potenti
role
pathway
psav
life
cycl
control
infect
found
pathway
activ
psav
life
cycl
activ
provir
effect
via
inhibit
product
furthermor
determin
express
vpg
propol
protein
psav
suffici
induc
cox
express
product
among
solubl
factor
produc
respons
host
cell
viral
infect
well
known
antivir
repertoir
immunolog
system
induc
no
ino
induc
cytokin
transcript
level
primarili
macrophag
neutrophil
epitheli
cell
hepatocyt
produc
high
concentr
ino
enzym
respons
product
regul
pathway
product
known
restrict
vesicular
stomat
viru
vsv
infect
effect
thought
offset
induct
product
vsv
replic
vivo
show
activ
pathway
also
enhanc
psav
replic
inhibitori
effect
product
product
significantli
enhanc
patient
suffer
gastroenter
observ
noroviru
rotaviru
infect
children
secret
trigger
vitro
vivo
rotaviru
nonstructur
protein
turn
may
caus
diarrhea
elev
intestin
permeabl
regul
intestin
motil
intestin
ion
transport
contrast
rotaviru
infect
littl
product
observ
psav
replic
llcpk
cell
possibl
due
synthesi
suggest
may
involv
sapovirusinduc
diarrhea
howev
import
note
fulli
rule
potenti
role
psav
pathogenesi
vivo
cellular
respons
infect
influenc
numer
cell
type
may
entir
reproduc
immort
cell
vitro
instanc
viral
protein
shown
stimul
activ
pathway
often
act
either
directli
indirectli
transcript
transactiv
gene
express
among
viral
protein
activ
report
hepat
c
viru
hcv
protein
viral
serin
proteas
known
enhanc
pathway
activ
multipl
signal
pathway
addit
sever
acut
respiratori
syndrom
coronaviru
sarscov
nucleocapsid
protein
also
activ
express
pathway
bind
directli
regulatori
element
ccaatenhanc
bind
protein
present
studi
demonstr
express
psav
vpg
propol
protein
isol
suffici
lead
activ
pathway
mechan
behind
activ
remain
determin
subject
futur
studi
present
studi
level
mrna
protein
increas
respons
psav
infect
evalu
effect
nonselect
inhibitor
psav
replic
among
inhibitor
test
inhibitor
celecoxib
nonselect
inhibitor
indomethacin
exert
stronger
antipsav
effect
inhibitor
decreas
viru
yield
rna
synthesi
howev
inhibitor
weaker
inhibitori
effect
psav
replic
like
due
less
potent
activ
fact
higher
concentr
requir
effect
cox
inhibit
result
cell
toxic
observ
use
addit
robust
inhibitori
effect
inhibitor
nonselect
inhibitor
indomethacin
psav
replic
observ
posttreat
preposttreat
reason
posttreat
inhibitor
stronger
effect
preposttreat
remain
unknown
one
possibl
could
offtarget
effect
use
high
dose
inhibitor
llcpk
cell
although
publish
report
kind
phenomena
present
studi
observ
transient
increas
level
psav
infect
wherea
induct
significantli
induc
induct
sustain
later
stage
viral
life
cycl
howev
dramat
effect
nonselect
cox
inhibitor
indomethacin
inhibitor
coxspecif
sirna
support
hypothesi
enzym
play
role
psav
replic
conclus
result
demonstr
crucial
role
pathway
regul
product
psav
replic
provid
environ
suitabl
effici
psav
growth
addit
data
indic
pharmacolog
target
could
provid
potenti
target
strategi
control
sapoviru
infect
facilit
antivir
effect
product
studi
requir
determin
target
pathway
vivo
neg
impact
psav
pathogenesi
llcpk
porcin
kidney
cell
obtain
american
type
cultur
collect
atcc
maintain
eagl
minim
essenti
medium
emem
contain
fetal
bovin
serum
fb
uml
penicillin
streptomycin
tissu
cultureadapt
psav
strain
cowden
recov
fulllength
infecti
clone
propag
llcpk
cell
supplement
bile
acid
celecoxib
nimesulid
purchas
cayman
chemic
ann
arbor
mi
usa
gcdca
dimethyl
sulfoxid
dmso
lname
indomethacin
sigmaaldrich
st
loui
mo
usa
sirna
sirna
scrambl
sirna
purchas
santa
cruz
biotechnolog
inc
santa
cruz
ca
usa
monoclon
antibodi
mab
mous
polyclon
antibodi
rabbit
obtain
abcam
cambridg
usa
mous
mab
ha
tag
purchas
origen
rockvil
md
usa
synthet
purchas
tocri
bioscienc
ellisvil
mo
usa
antipsav
capsid
mab
antipsav
vpg
polyclon
antibodi
previous
describ
secondari
antibodi
use
horseradish
peroxidaseconjug
goat
immunoglobulin
rabbit
igg
cell
signal
beverli
usa
mous
igg
santa
cruz
fluorescein
isothiocyan
fitc
conjug
goat
immunoglobulin
rabbit
igg
jackson
immuno
research
laboratori
west
grove
pa
usa
cytotox
chemic
use
studi
determin
use
tetrazolium
bromid
mtt
assay
accord
manufactur
instruct
briefli
cell
plate
incub
medium
contain
differ
concentr
variou
chemic
h
remov
medium
mtt
solut
ad
well
incub
h
incub
well
supplement
dmso
incub
room
temperatur
min
absorb
optic
densiti
od
read
enzymelink
immunosorb
assay
elisa
reader
nm
percent
cell
viabil
calcul
use
follow
formula
odsampl
odblank
odcontrol
odblank
nontox
concentr
chemic
use
studi
llcpk
cell
grown
plate
attain
desir
confluenc
chemic
inhibitor
dissolv
dmso
make
mm
stock
concentr
appropri
seri
dilut
made
dilut
appropri
volum
chemic
inhibitor
stock
emem
treatment
group
typic
follow
mock
treatment
pretreat
posttreat
preposttreat
confluent
llcpk
cell
pretreat
variou
concentr
inhibitor
h
cell
wash
phosphatebuff
salin
pb
ph
inocul
psav
multipl
infect
moi
fluoresc
focu
unit
ffu
cell
posttreat
group
differ
concentr
inhibitor
ad
mainten
medium
viru
adsorpt
step
preposttreat
group
llcpk
cell
pretreat
differ
concentr
inhibitor
h
remov
inhibitor
cell
wash
twice
pb
inocul
psav
inhibitor
ad
end
viru
adsorpt
period
region
code
psav
protein
amplifi
fulllength
infecti
clone
pcr
assay
primer
pair
contain
sali
nhei
restrict
enzym
site
tabl
forward
primer
specif
abovement
gene
ntermin
ha
tag
sequenc
tabl
amplicon
purifi
purigel
invitrogen
waltham
usa
follow
manufactur
instruct
subclon
puno
clone
vector
invivogen
san
diego
ca
usa
amplifi
region
verifi
sanger
sequenc
llcpk
cell
grown
plate
individu
transfect
plasmid
construct
differ
viral
gene
insert
empti
vector
use
lipofectamin
reagent
invitrogen
follow
manufactur
instruct
cell
harvest
differ
posttransfect
point
subject
quantit
realtim
pcr
western
blot
analysi
use
antiha
antibodi
llcpk
cell
seed
plate
transfect
cap
vitrotranscrib
psav
rna
use
lipofectamin
invitrogen
cap
vitro
transcript
deriv
fulllength
psav
cdna
clone
mmessag
mmachin
kit
ambion
austin
tx
usa
follow
manufactur
instruct
transfect
perform
h
medium
replenish
emem
supplement
gcdca
six
day
posttransfect
cell
lyse
harvest
subject
immunoblot
qpcr
analyz
psav
vpg
level
llcpk
cell
cultur
cultur
plate
confluenc
transfect
sirna
pmol
scrambl
control
sirna
use
lipofectamin
reagent
invitrogen
follow
manufactur
instruct
cell
infect
psav
moi
ffucel
h
unadsorb
virus
remov
cell
maintain
emem
fb
gcdca
cell
harvest
differ
time
point
subject
qpcr
median
tissu
cultur
infect
dose
western
blot
analys
confluent
llcpk
cell
plate
infect
psav
treat
chemic
inhibitor
transfect
sirna
transfect
gene
construct
psav
harvest
differ
time
point
cell
wash
twice
pb
lyse
cell
extract
buffer
invitrogen
supplement
proteas
phosphatas
inhibitor
roch
basel
switzerland
total
cell
lysat
denatur
resolv
sodium
dodecyl
sulfat
sd
polyacrylamid
gel
resolv
protein
transfer
nitrocellulos
blot
membran
amersham
protran
ge
healthcar
life
scienc
germani
immunoblot
primari
antibodi
specif
glyceraldehyd
dehydrogenas
gapdh
ha
psav
vpg
secondari
antibodi
rabbit
mous
igg
appli
primari
antibodi
immunoreact
band
develop
use
enhanc
chemiluminesc
reaction
kit
dogen
seoul
south
korea
imag
taken
use
davinchwestern
imag
system
young
ltd
kangnam
seoul
south
korea
confirm
equal
protein
load
blot
membran
also
incub
antibodi
gapdh
reactiv
compar
intens
target
band
quantif
protein
densiti
perform
use
imag
studio
lite
licor
biotechnolog
lincoln
ne
usa
normal
correspond
densiti
gapdh
sampl
quantifi
intracellular
rna
level
signal
molecul
mock
psavinfect
chemic
inhibitortr
sirnatransfect
cell
wash
twice
pb
scrape
collect
clean
microtub
sampl
centrifug
rpm
min
total
rna
isol
use
purelink
rna
minikit
ambion
life
technolog
carlsbad
ca
usa
follow
manufactur
instruct
quantifi
psav
rna
mock
psavinfect
chemic
inhibitortr
sirnatransfect
cell
freezethaw
three
time
cell
debri
spun
g
min
supernat
along
remain
bulk
sampl
collect
store
use
total
rna
extract
supernat
use
rneasi
kit
qiagen
follow
manufactur
instruct
rna
concentr
spectrophotometr
determin
nm
use
biophotomet
plu
eppendorf
hamburg
germani
cdna
prepar
use
rna
revers
transcrib
use
random
hexam
promega
madison
wi
usa
oligonucleotid
primer
use
quantit
realtim
pcr
design
publish
sequenc
psav
vpg
tabl
reaction
mixtur
set
volum
contain
pmol
forward
revers
primer
cdna
topreal
qpcr
premix
enzynom
daejon
south
korea
amplif
profil
follow
cycl
initi
denatur
min
cycl
denatur
primer
anneal
extens
amplif
profil
vpg
includ
denatur
min
follow
cycl
denatur
primer
anneal
extens
rel
express
level
calcul
use
sampl
normal
quantiti
gene
copi
number
vpg
gene
calcul
use
dilut
known
amount
gener
standard
curv
assay
perform
previous
describ
briefli
serial
dilut
clarifi
viru
supernat
prepar
emem
dilut
inocul
monolay
llcpk
cell
grown
plate
supplement
gcdca
incub
incub
viru
titer
calcul
day
postinfect
express
valu
method
reed
muench
infect
assay
carri
describ
previous
briefli
confluent
monolay
cell
confoc
dish
treat
variou
inhibitor
chemic
describ
mocktreat
inhibitortr
cell
infect
psav
moi
ffucel
incub
h
cell
wash
three
time
pb
move
mainten
medium
incub
h
prior
fix
formaldehyd
pb
immunofluoresc
assay
perform
previous
report
briefli
fix
cell
chamber
slide
permeabil
addit
triton
incub
room
temperatur
min
wash
pb
contain
newborn
calf
serum
pbsnc
chamber
slide
supplement
antipsav
capsid
dilut
mab
incub
overnight
cell
wash
three
time
pbsnc
fitcconjug
goat
secondari
antibodi
dilut
ad
wash
pb
chamber
mount
slowfad
gold
antifad
reagent
life
technolog
eugen
usa
contain
dapi
solut
nuclear
stain
infect
cell
observ
lsm
confoc
microscop
analyz
use
lsm
softwar
carl
zeiss
calcul
percentag
antigenposit
cell
cell
well
count
use
object
eyepiec
yield
final
magnif
number
antigenposit
cell
mock
drugtreat
scrambl
rna
sirna
gene
compar
concentr
cultur
supernat
mock
psavinfect
cell
presenc
absenc
chemic
inhibitor
determin
assay
nitrit
one
stabl
end
product
collect
supernat
centrifug
remov
cell
debri
assay
done
use
griess
reagent
system
promega
madison
wi
usa
accord
manufactur
instruct
briefli
equal
volum
experiment
sampl
sulfanilamid
solut
incub
room
temperatur
min
equal
volum
dihydrochlorid
solut
ad
well
incub
min
absorb
read
nm
plate
reader
nitrit
concentr
sampl
determin
compar
gener
nitrit
standard
calcul
linear
regress
analysi
